Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mega Genomics Limited
美因基因有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

INSIDE INFORMATION
DELAY IN PUBLICATION OF 2025 INTERIM RESULTS
AND
CONTINUED SUSPENSION OF TRADING

This announcement is made by Mega Genomics Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 1 April 2025, 22 April 2025, 30 April 2025, 5 May 2025 and 30 May 2025 (the "**Announcements**") in relation to, among other matters, (i) delay in publication of the 2024 Annual Results, (ii) postponement of the Board meeting, (iii) delay in publication of the 2024 Annual Report, (iv) proposed change of the auditor; and (v) resumption guidance from the Stock Exchange. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcements.

Pursuant to Rules 13.49(6) of the Listing Rules, the Company is required to publish its interim results announcement for the six months ended 30 June 2025 (the "**2025 Interim Results**") not later than two months after the date upon which the financial period ended, that is, on or before 31 August 2025.

Due to the matters set out in the Announcements, the publication of the 2024 Annual Results and despatch of the 2024 Annual Report are still pending as of the date of this announcement. The publication of the 2025 Interim Results is therefore expected to be delayed within the prescribed time in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025 and will remain suspended until further notice. Further announcement(s) will be made by the Company as and when appropriate and in accordance with the Listing Rules.

Shareholders and prospective investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 29 August 2025

As of the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*